Nexavar sorafenib: Phase III data

The double-blind, international Phase III SEARCH trial in 720 patients with unresectable HCC showed that twice-daily 400 mg oral Nexavar plus once-daily 150 mg oral Tarceva erlotinib missed the primary endpoint of OS vs. Nexavar plus placebo. Details were not disclosed. Nexavar is approved in more than 100 countries to treat liver cancer and advanced kidney cancer. Bayer and Onyx have a worldwide co-development agreement for Nexavar outside of Japan, where Bayer owns rights. ...